Jay Metz advises individual executives, public and private companies, and compensation committees on a broad array of compensation and benefits issues in the context of day-to-day business, corporate transactions, and crisis situations.
Mr. Metz regularly designs compensation plans and advises clients with respect to tax, securities, and corporate law issues that arise in connection with establishing and administering plans, including:
- Stock option and other equity incentive plans
- Phantom equity, carveout, and other retention plans
- Employee stock purchase plans
- Nonqualified deferred compensation plans
- Incentive compensation plans and arrangements
Mr. Metz represents clients with respect to compensation and benefits issues in a variety of corporate transactions, including:
- Corporate mergers and acquisitions
- Initial public offerings
He regularly works with employers and executives to negotiate, design, and document executive employment, change in control, and severance agreements. In addition, he advises companies on matters affecting tax-qualified retirement plans, and health and welfare programs.
Prior to attending law school, Mr. Metz was the Chief Financial Officer of an independent physician association and health maintenance organization. He also served several years in the United States Air Force as a cryptologic linguist.
Mr. Metz's representative transactions include:
- Broadcom Limited’s (f.k.a. Avago Technologies) US$37 billion acquisition of Broadcom Corporation
- Alios BioPharma’s US$1.75 billion sale to Johnson & Johnson
- Integrated Device Technology’s US$250 million acquisition of GigPeak
- Thoratec Corporation’s US$3.475 billion sale to St. Jude Medical
- Kythera Biopharmaceutical’s US$2.1 billion sale to Allergan
- OpenTable’s US$2.6 billion sale to Priceline
- Sienna Biopharmaceuticals’ US$74 million initial public offering
- e.l.f. Beauty’s US$141 million initial public offering
- Aimmune Therapeutics’ US$183 million initial public offering
- Ascendis Pharma’s US$124 million initial public offering
- Nevro Corp.’s US$144 million initial public offering